Neeraj Agarwal, MD:What is the rationale for choosing cabozantinib over the ipilimumab/nivolumab combination in this patient? So, first of all, the ipilimumab/nivolumab combination is not available. It’s not FDA approved. Moving forward 2 months or 3 months, assuming this combination is approved, I still think cabozantinib would be a better choice in this given patient because the PD-L expression of the tumor was less than 1%. And if we look at the CheckMate-214 trial data, the progression-free survival was not experienced by those patients whose tumor did not express PD-L1. So, in my view, for this given patient, cabozantinib would be a better choice.
So, regarding safety and toxicity of cabozantinib versus the ipilimumab/nivolumab combination, I think these drugs are very different with their own safety and toxicity profile. Cabozantinib is a very traditional VEGF TKI, which also targets AXL and MET. And accordingly, we see toxicities more in line with VEGF TKIs, such as hand-foot syndrome, hypertension, fatigue, diarrhea, and so on. On the other hand, the ipilimumab/nivolumab combination is a very novel combination. It is an already established combination in metastatic melanoma, but for GU oncologists, it’s a very novel combination with its own novel set of side effects and safety profile. Safety toxicity profile of the nivolumab/ipilimumab combination is very different from a TKI like cabozantinib. We are mainly talking about autoimmune side effects. So, if we look at the CheckMate-214 trial, 60% of patients required frequent treatment with corticosteroids, which is, in my view, a relatively higher use of steroids, more than I have practiced in my clinic with single-agent nivolumab.
Transcript edited for clarity.
Case Scenario: A 73-year old female with rapidly progressing mRCC
March 2017
December 2017
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk mRCC
July 8th 2024During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.
Read More